Shire Lays a Stake in Vaccines

Shire has been buffeted by management upheaval and generic and branded competition. But the group's foray into vaccines is a sensible long-term bet, offering it a low-risk route into R&D.

Shire PLC , which in-licenses marketed or close-to-market drugs in specialist areas, has been one of the industry's fastest-growing firms, driven by an aggressive acquisition strategy and strong marketing.

But shareholders are becoming disenchanted. In the first place, the firm's most important product, Adderall, a mixture of four amphetamine...

In Vivo Podcast

Candid conversations with C-suite leaders.

Keep up with strategy, innovation and evolving trends across life science industries.

More from Global Vision

More from In Vivo